H. pylori

Question 1

In treatment-naive patients w/ H. pylori infection, optimized BQT is recommended as a first-line treatment option

Answer 1

strong, moderate evidence

Question 2

In treatment-naive patients w/ H. pylori infection, rifabutin triple therapy is suggested as a first-line treatment option

Answer 2

conditional, low quality evidence

Question 3

In treatment-naive patients w/ H. pylori infection, dual therapy w/ a PCAB and amoxicillin is suggested as a first-line treatment option

Answer 3

conditional, moderate evidence

Question 4

In treatment-naive patients w/ H. pylori infection and unknown clarithromycin susceptibility, PCAB-clarithromycin triple therapy is suggested over PPI-clarithromycin triple therapy

Answer 4

conditional, moderate evidence

Question 5

In treatment-naive patients w/ H. pylori infection, concomitant therapy is not suggested over bismuth quadruple therapy

Answer 5

conditional, low evidence

Question 6

In treatment-experienced patients w/ persistent H. pylori infection who have not previously received bismuth quadruple therapy, optimized bismuth quadruple therapy is suggested

Answer 6

conditional, very low evidence

Question 7

In treatment-experienced patients w/ persistent H. pylori infection who have previously received PPI-clarithromycin triple therapy, optimized bismuth quadruple therapy is suggested

Answer 7

conditional, low evidence

Question 8

In treatment-experienced patients w/ persistent H. pylori infection who have received bismuth quadruple therapy, rifabutin triple therapy is suggested

Answer 8

conditional, low evidence

Question 9

In treatment-experienced patients w/ persistent H. pylori infection who have not received optimized bismuth quadruple therapy, optimized bismuth quadruple therapy is suggested over quinolone-based therapy

Answer 9

conditional, low evidence

Question 10

In treatment-experienced patients w/ persistent H. pylori infection, levofloxacin triple therapy is suggested in patients w/ known levofloxacin-sensitive H. pylori strains and when optimized bismuth quadruple or rifabutin triple therapies have previously been used or are unavailable

Answer 10

conditional, low evidence

Question 11

In treatment-experienced patients w/ persistent H. pylori infection, there is insufficient evidence from North America to recommend high-dose PPI or PCAB dual therapy

Answer 11

no recommendation, evidence gap

Question 12

There is insufficient evidence to suggest that the use of probiotic therapy improves the efficacy or tolerability of H. pylori eradication therapy

Answer 12

conditional, low evidence